Welcome to our dedicated page for Creative Med Technology Hldgs news (Ticker: CELZ), a resource for investors and traders seeking the latest updates and insights on Creative Med Technology Hldgs stock.
Creative Medical Technology Holdings, Inc. develops regenerative medicine and immune-cell therapies as a clinical-stage biotechnology company trading under CELZ. Company news centers on CELZ-201, or olastrocel, an allogeneic/perinatal tissue-derived cell therapy evaluated in the FDA-cleared ADAPT trial for chronic lower back pain associated with degenerative disc disease, and on platform extensions such as Ultrasome for knee osteoarthritis.
Recurring updates also cover WHO International Nonproprietary Name activity for cell-therapy assets, CELZ-101 Treg immunotherapy work, and BioDefense Inc., a wholly owned subsidiary focused on burn pit exposure research using iPSC technology, AI-enabled molecular modeling, and regenerative countermeasure development.
Creative Medical Technology Holdings, Inc. (OTC – CELZ) announced promising data on ImmCelz®, revealing that its administration significantly increases hepatocyte growth factor (HGF-1) in treated animals. This study indicates that the therapeutic effects of ImmCelz® are contingent upon HGF-1. The company has previously identified therapeutic activity in various diseases, including rheumatoid arthritis and stroke. The CEO emphasized the importance of understanding biological mechanisms for attracting investments in regenerative immunotherapy, leading to new patent applications based on these findings.
Creative Medical Technology Holdings (CELZ) announced promising proof of concept studies for its ImmCelz® immunotherapy in a collagen-induced rheumatoid arthritis model. The studies highlighted that ImmCelz® effectively suppresses harmful autoimmunity without compromising normal immune functions, potentially reducing treatment-related infection risks. CEO Timothy Warbington noted the potential for rapid clinical application of these findings. ImmCelz® utilizes reprogrammed immune cells derived from adult stem cells, aiming at a significant multi-billion dollar market for autoimmune conditions.
Creative Medical Technology Holdings (OTC-CELZ) has provided an update on its corporate activities, showcasing growth in its stem cell programs. The CaverStem program is expanding, with record kit orders and new practitioners in Houston and Scottsdale. The FemCelz program is gaining traction, and marketing efforts are set to increase. A patent approval for OvaStem highlights progress in treating ovarian failure. The TregSpine and AmnioStem programs are advancing, with an IND application expected in Q4 2020. Despite challenges, the company remains optimistic about its growth.
Creative Medical Technology Holdings announced a Notice of Allowance for its patent on using T regulatory cells to enhance blood circulation for lower back pain treatment. This patent is vital as many patients suffer from poor circulation, contributing to pain. The company also holds a prior patent for stem cell therapy for lower back pain. The CEO highlighted the growing market for such therapies, citing a $1 billion deal in the sector. They are focused on expanding their intellectual property and welcome collaborations within the biotechnology community.
Creative Medical Technology Holdings (CELZ) announced new findings showing that AmnioStem® stem cells can effectively suppress stroke-related pathological molecules. These cells block harmful cytokine production and reprogram macrophages from a damaging to a reparative role, offering a potential advantage over other treatments. The company plans to publish this data and include it in its FDA IND submission. This positions the firm favorably, aiming for FDA clearance and stronger intellectual property protection.